Recent Updates
Recently added Catalysts
EOLS Positive Sentiment

Evolus Expands Strategic Partnership with Symatese to Commercialize Estyme® in Canada, Australia, and New Zealand

Key Takeaway: Evolus, Inc. has expanded its strategic partnership with Symatese, granting it exclusive rights to commercialize the Estyme® collection of injectable hyaluronic acid gels in Canada, Australia, and New Zealand. This amendment to their existing licensing and distribution agreement is expected to enhance Evolus' market presence and product offerings in these regions.

Market Sentiment Analysis

POSITIVE FACTORS

  • Evolus expands its market reach in Canada, Australia, and New Zealand.
  • The partnership with Symatese enhances Evolus' product portfolio.
  • Exclusive rights to commercialize Estyme® could boost sales.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
PrabotulinumtoxinA-Xvfs
Phase 2 · Glabellar Frown Lines

Full Press Release Details

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it has expanded its partnership with Symatese through an amendment to the companies’ existing licensing and distribution agreement, providing Evolus with the exclusive rights to commercialize the Estyme® (pronounced “esteem”) collection of injectable hyaluronic acid (HA) gels in Canada, Australia, and New Zea

Frequently Asked Questions

What is the Estyme® collection?

The Estyme® collection consists of injectable hyaluronic acid gels.

Which regions will Evolus commercialize Estyme®?

Evolus will commercialize Estyme® in Canada, Australia, and New Zealand.

What does the partnership with Symatese entail?

The partnership allows Evolus exclusive rights to distribute Estyme® in specified regions.

How will this partnership benefit Evolus?

This partnership is expected to enhance Evolus' market presence and product offerings.

Last updated: Aug 4, 2026